Key Takeaways:Both Eli Lilly and CVS Health reported their Q2 2026 earnings on Wednesday, delivering results that soundly outpaced expectations. With earnings this potent, the State Street Health Care Select Sector SPDR ETF (XLV) is offering a stronger use case, given how it invests noticeably in both companies, especially Eli Lilly. Eli Lilly Produces Breakout Q2 Results, Elevated GuidanceTo get things started, Eli Lilly began the day on a high note. CVS Health also posted its Q2 2026 earnings, and likewise blew past expectations and raised its annual guidance. These allocations include investments to both CVS and Eli Lilly, but XLV has a particularly heavy portfolio tilt towards Eli Lilly.